Cynata Therapeutics Limited has released a press release.
CYP-001 GvHD Trial Primary Evaluation Results
Earlier from Cynata Therapeutics
- Suspension from Quotation
- EU Positive Opinion on CYP-001 Paediatric Investigation Plan
- Cynata Secures Commitments for $1.5m Placement
- March 2026 Quarterly Activity Report & Appendix 4C